Epigenetic silencing schlafen-11 sensitizes esophageal cancer to ATM inhibitor

Figure 5 Invivo efficacy of sensitivity of Schlafen-11 deficient cells to AZD0156. A: Schematic diagram of xenograft mouse models generation and medication; B: Tumors derived from Schlafen-11 (SLFN11) unexpressed and re-expressed KYSE30 cell xenografts in mice treated as indicated; C: Growth curves of xenograft tumors treated with 2 mg/kg cisplatin, 30 mg/kg AZD0156 and combination of 2 mg/kg cisplatin plus 30 mg/kg AZD0156; D and E: Normalized tumor volume and weight in KYSE30 unexpressed and re-expressed xenografts under different modes of treatment, statistical significance was analyzed by t test (^dP < 0.0001); F: Schematic model of synthetic lethality of SLFN11 with ATM inhibitor in esophageal squamous cell carcinoma cells.